Phenolic compounds isolated from fermented blueberry juice decrease hepatocellular glucose output and enhance muscle glucose uptake in cultured murine and human cells by Abir Nachar et al.
RESEARCH ARTICLE Open Access
Phenolic compounds isolated from
fermented blueberry juice decrease
hepatocellular glucose output and enhance
muscle glucose uptake in cultured murine
and human cells
Abir Nachar1,2, Hoda M. Eid1,2,3, Melinda Vinqvist-Tymchuk4, Tri Vuong5, Wilhelmina Kalt4, Chantal Matar5
and Pierre S. Haddad1,2*
Abstract
Background: We recently reported that blueberry juice fermented (FJ) with Serratia vaccinii bacterium has
antidiabetic activities both in vivo and in vitro. The purpose of this project was to elucidate the effect of FJ on
glucose homeostasis in liver and skeletal muscle cells and to identify active fractions/compounds responsible for
this effect.
Methods: FJ was fractionated using standard chromatography procedures. Hepatic (H4IIE, HepG2) and skeletal
muscle cells (C2C12) were treated with maximum non-toxic concentrations of FJ, fractions and isolated compounds
thereof. Glucose-6-phosphatase (G6Pase) activity was measured using glucose oxidase method. To measure glucose
uptake and glycogen synthase (GS) activity, radioactive assays were used.
Results: Fractionation of FJ yielded seven fractions. FJ and its phenolic fractions F2, F3-1 and F3-2 respectively
inhibited G-6Pase by 31, 45, 51 and 26%; activated GS by 2.3-, 2.3-, 2.2- and 2-fold; and stimulated glucose uptake
by 19, 25, 18 and 15%, as compared to DMSO vehicle control. Subfractionation of the active fractions yielded 4
compounds (catechol, chlorogenic, gallic and protocatechuic acid). Catechol, yielding the greatest bioactivity in
G6Pase and glucose uptake assays, decreased G6Pase activity by 54%, increased GS by 2-fold and stimulated
glucose uptake by 44% at 45.5 μM.
Conclusions: This study identifies novel potential antidiabetic compounds that can help standardize FJ.
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Background
Type 2 diabetes (T2D) is a chronic metabolic disease
that affects 382 million people worldwide and is associ-
ated with many complications, especially cardiovascular
diseases [1]. Insulin resistance plays a major role in the
physiopathology of type 2 diabetes. It is associated with
an impaired insulin stimulation of glucose transport in
muscle and fat as well as an impaired suppression of
hepatic glucose production [2]. Nowadays, several
people are using natural health products alone or in
combination with their hypoglycemic drugs to manage
their T2D. Currently, more than one third of Canadian
diabetic patients are using alternative medicine [3, 4].
Members of the Vaccinium genus (family Ericaceae),
notably Vaccinium angustifolium Ait (Canadian lowbush
blueberry), are well known for their antidiabetic activ-
ities and have been used in the traditional medicine of
many populations to treat T2D [5–8]. Previous studies
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have shown that different parts of the V. angustifolium
plant reduces insulin resistance in obese rats [9] and
possess insulin-like, glitazone-like and cytoprotective ef-
fects [10]. Blueberry fruits are rich in phenolic com-
pounds with antidiabetic properties [8, 11]. Interestingly,
the biotransformation of blueberry juice by a bacterium
called Serratia vaccinii was found to greatly increase its
content in phenolic compounds and its antioxidant
activity [12].
This process also had an impact on the antidiabetic
potential of blueberry juice. Indeed, fermented blueberry
juice (FJ), in contrast to normal juice, stimulated glucose
uptake in muscle cells and adipocytes using an insulin-
independent pathway implicating the phosphorylation of
AMP-activated protein kinase (AMPK) [13]. This antidi-
abetic effect was validated in an animal model using KK-
Ay hyperphagic mice [14].
Glucose homeostasis results from equilibrium between
the intestinal absorption of glucose, its production by
the liver and its utilization by peripheral tissues such as
muscle and fat [15]. Insulin regulates hepatic glucose
production and storage. It inhibits some transcription
factors like the forkhead family and the Peroxisome
proliferator-activated receptor-gamma coactivator-1α
(PGC-1α) leading to a decrease in the activity of
Glucose-6-phosphatase (G6Pase), a key enzyme impli-
cated in hepatic glucose production [16, 17]. On the
other hand, insulin signaling phosphorylates glycogen
synthase kinase-3 (GSK-3) leading to the activation of
glycogen synthase (GS), a key enzyme implicated in glu-
cose storage [18]. In addition, insulin regulates glucose
uptake and utilization in muscle through the stimulation
of glucose transporter 4 (GLUT4) translocation to the
plasma membrane in order to mediate facilitative glu-
cose diffusion [19].
In continuity with aforementioned studies on FJ in
muscle cells and adipocytes, the aim of this project is to
elucidate the antidiabetic action of FJ at the level of glu-
cose homeostasis in cultured hepatocytes and muscle
cells. Importantly, our purpose is to identify active frac-




All cell lines used – H4IIE (rat hepatoma), HepG2 (human
hepatoma) and C2C12 (murine skeletal myoblasts) – were
purchased from American Type Culture Collection
(ATCC; Manassas, VA, USA). H4IIE cells were grown in a
high glucose Dubelcco’s Modified Eagle Medium (DMEM)
containing 10% Fetal Bovin Serum (FBS) and 0.5% antibi-
otics (PS: Penicillin 100 U/mL, Streptomycin 100 μg/mL).
HepG2 cells were grown in DMEM/F12 (50/50) medium,
containing 10 FBS and 0.5% PS. On the other hand,
C2C12 myocytes were cultured in DMEM medium con-
taining 10 FBS, 10 HS and 0.5% PS then switched to
DMEM medium containing 2% HS to initiate differenti-
ation. Glucose uptake assay was performed on differenti-
ated myotubes at the 7th day of differentiation. All cells
were cultured and incubated at 37 °C with 5% CO2 in 12-
well plates for glucose uptake and G6Pase experiments
and in 6-well plates for GS experiments. Overnight treat-
ment (16–18 h) with the different samples was initiated
prior to the determinations.
Preparation of fermented blueberry juice
Mature lowbush blueberry fruits were purchased from
Cherryfield Foods Inc. (Cherryfield, Maine, USA). The
species was identified by the plant taxonomist Dr. Alain
Cuerrier (Montreal Botanical Garden). The frozen fruit
preparation represents a homogeneous mixture of sev-
eral genotypes provided by many wild blueberry pro-
ducers from Canada and Northeastern United States.
We selected this starting material because it appropri-
ately represents what is regularly used in the industry to
prepare commercial wild blueberry juice. For the pur-
poses of this study, blueberry fruit mixture (hereafter
called juice) was prepared by blending the fruits (100 g)
with an equivalent quantity (100 g) of Minimal Broth
Davis without dextrose (MM) (Difco Laboratories,
Detroit, MI, USA). The fruit mixture was then centri-
fuged to remove insoluble particles. The resulting juice
was sterilized using 0.22 μm Express Millipore filters
(Millipore, Etobicoke, ON, Canada).
Serratia vaccinii were cultured as previously described
[12]. The juice was inoculated with a saturated culture
of Serratia vaccinii at (7.5 ± 0.3) log CFU ml − 1 corre-
sponding to 2% of the total juice volume. A control flask
was prepared under the same conditions but without in-
oculation. The blueberry preparations were incubated in
a Lab-Line low-temperature benchtop incubated shaker
(Lab-Line Instruments, Inc, Melrose Park, IL, USA) in
250-ml flasks at 22 °C, 120 rev min − 1, under aerobic
conditions. After a 4 day fermentation period, the FJ was
sterilized by 0.22 μm filtration as detailed elsewhere [12].
In order to facilitate the handling and insure the stabil-
ity of the blueberry preparations, they were freeze-dried
to produce powdered material that was kept at −20 °C
until use.
Fractionation of FJ and identification of active
compounds
Organic solvents were purchased from Fisher Scientific
(Burlington, ON, Canada), unless otherwise mentioned.
Normal blueberry juice has been partially characterized
elsewhere [12, 13, 20, 21]. In the present studies, we car-
ried out further phytochemical analysis using HPLC as
described below. Figure 1 shows the fractionation
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scheme that was carried out to identify active com-
pounds present in fermented blueberry juice (FJ). The
starting material for the fractionation process was either
normal blueberry juice prepared from wild blueberries
(the control Juice, CJ), or the FJ in batches of approxi-
mately 500 ml. These were placed onto 29.5 cm × 5 cm
chromatography columns (pre-conditioned with 1 col-
umn volume methanol then 2 column volumes water)
containing Waters preparative C18 resin (125 Å, 55–
105 μ) then washed with 2 column volumes of water,
which was sufficient to remove sugars and organic acids
(discarded). The phenolic compounds were eluted from
the column using 1.2 column volumes of 13 mM tri-
fluoroacetic acid (Sigma Aldrich, Oakville, ON) in etha-
nol. The ethanol eluent was dried using rotary
evaporation and lyophilized to give the Phenolic fraction
(F2). The CJ underwent no further fractionation after
this initial step. On the other hand, a portion of F2 was
dissolved in water and further fractionated on C18 col-
umn as outlined above. The first subfraction (F2.1) was
eluted using 4 column volumes of 0.16 M HCl (Ricca
Chemical Company, Texas, USA) and 2.06 M ethanol in
water. This subfraction was composed mainly of gallic
acid, protocatechuic acid, and catechol, as confirmed by
HPLC (comparing retention times and UV-vis profiles of
the peaks to standards). The next subfraction (F2.2) was
eluted using an additional 2 column volumes of 0.16 M
HCl and 2.06 M ethanol in water and was rich in chloro-
genic acid (as confirmed by HPLC). The remaining
bound materials, mainly flavonoids, were eluted using
0.16 M HCl and 13.7 M ethanol in water and were called
the flavonoid fraction (F2.3). The three fractions were
dried using rotary evaporation and lyophilisation. Next,
a portion of the F2.3 fraction was dissolved in 4.28 M
ethanol and applied to a 34.5 cm × 5 cm lipophilic
Sephadex column (LH-20, 25–100 μ, Sigma Aldrich,
Oakville, ON, Canada). HCl was neutralized and three
fractions were collected. The first fraction enriched in
anthocyanins (F2.3.1) was eluted using 7 column vol-
umes of 4.28 M ethanol. The second fraction enriched
in heteropolymers (F2.3.2) was then eluted using 3 col-
umn volumes of 8.56 M ethanol. Finally, a third fraction
Fig. 1 Fractionation Process for Fermented Blueberry Juice
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enriched in proanthocyanidins (F2.3.3) was eluted using
3 column volumes of 9.53 M acetone. All three fractions
were dried using rotary evaporation and lyophilisation.
HPLC analysis of normal and fermented blueberry juice
The HPLC system used was an Agilent 1100 binary
pump system (Agilent Technologies, Mississauga, ON,
Canada) with thermostatted column chamber, refriger-
ated autosampler, degasser, and DAD detection. Samples
were separated on an Agilent Zorbax SB-C18 2.1×50mm
1.8 μ column held at 26 °C. Samples were held at 4 °C in
the autosampler. Elution was done using a two solvent
gradient (solvent A was 8 ml trifluoroacetic acid (TFA)
per litre water (pH 1.35), solvent B was 6.8 ml TFA per
liter acetonitrile) at a flow rate of 0.4 mL/min as follows:
5-10% B (0–12.5 min), 10–20% B (12.5–43.75 min), 20–
100% B (43.75–45 min), hold 100% B 5 min, 100–5% B
(50–51 min), re-equilibrating 9 min before the next in-
jection. The following wavelengths were monitored:
280 nm (phenolics), 360 nm (flavonols), and 520 nm
(anthocyanins), and as well full spectra were recorded
from 190 to 600 nm. Designated pure compounds were
quantified using authentic standards (Sigma Aldrich,
Oakville, ON, Canada).
Cytotoxicity assay (LDH)
The cytotoxicity assay was based on a lactate dehydro-
genase (LDH) release kit (LDH Colorimetric Kit; Roche,
Mannheim, Germany) and served to determine max-
imum non-toxic concentration of each sample in H4IIE,
HepG2 and C2C12 cells. As was described previously
[22], the cells were treated overnight (16–18 h) with CJ,
FJ, fractions thereof, or pure compounds at different
concentrations. The culture media were collected separ-
ately for each condition and kept on ice (representing
released LDH from cells).
Then the cells were lysed by adding culture medium
with 1% Triton, for 10 min at 37 °C, 5% CO2 (represent-
ing cellular LDH). All the samples were centrifuged at
250×g, 4 °C for 10 min and kept on ice in Eppendorf
tubes. The ratio of released LDH to total LDH (total
LDH = released LDH + cellular LDH) was calculated for
each condition and results normalized to the values ob-
tained from cells treated with the vehicle control
(DMSO), always present at a final concentration of 0.1%.
Maximum non-toxic concentrations for each sample
were the highest ones that yielded LDH release compar-
able to that of DMSO controls.
Glusose-6-phosphatase (G6Pase) activity
H4IIE cell line was used to measure the activity of
G6Pase. Confluent cells were treated overnight (16–
18 h) with DMSO 0.1% (vehicle control), insulin 100 nM
(positive control), CJ, FJ, each of the seven fractions (at
5 μg/mL) or each of the four pure compounds, all at
their maximal non-toxic concentrations (Additional file 1:
Table S1). After the treatment, cells were rinsed with PBS
then lysed using a 15 mM phosphate buffer containing
0.05% Triton and 1.3 mM Phenol (pH = 6.5). A glucose-6-
phosphate-containing buffer (200 mM) was then added to
the cell lysates for 40 min at 37 °C; G-6-P contained in this
buffer served as a substrate for endogenous G6Pase to
yield glucose. A Wako AutoKit Glucose colorimetric assay
(Wako Chemicals, Richmond, VA, USA) was used to de-
termine the quantity of glucose generated in this reaction
according to manufacturers’ recommendations. The BCA
method was used to determine the protein content for
each condition. Results were expressed relative to vehicle
control (DMSO 0.1%).
Glycogen Synthase (GS) activity
HepG2 cells were used to measure GS activity since
this cell line exhibit a better expression of this en-
zyme compared to the H4IIE hepatocytes [23]. After
achieving confluence in 6 well plates, the cells were
treated overnight (16–18 h) with either vehicle control
(DMSO 0.1%), the maximal non-toxic concentrations of
CJ, FJ, each of the seven fractions (5 μg/mL) or each of the
four pure compounds (Additional file 1: Table S1). Treat-
ment with insulin at 100 nM for 15 min was used as
a positive control. After treatment, cells were rinsed
with PBS then lysed in a buffer solution containing
50 mM glycylglycine, 100 mM sodium fluoride,
20 mM EDTA, 0.5% glycogen, pH 7.4 and a complete
protease inhibitor cocktail added just before the
assay. The lysates were centrifuged at 1000×g for
20 min at 4 °C. After centrifugation, 30 μL of super-
natant from each condition were added to 100 μL of
a specific buffer solution to measure active GS
(25 mM glycylglycine, 0.275 mM UDP-glucose,
0.12 μCi/mL U-14C UDP-glucose, 1% glycogen, 1 mM
EDTA, 10 mM sodium sulfate, pH 7.5) and another
30 μL of supernatant were added to 100 μL of a spe-
cific buffer solution to measure total GS (25 mM
Tris, 5 mM UDP-glucose, 0.12 μCi/mL U-14C UDP-
glucose, 1% glycogen, 3 mM EDTA, 5 mM glucose-6-
phosphate, pH 7.9). The tubes were incubated in a
water bath at 30 °C for 120 min. After incubation,
90 μL of the mix for each condition was transferred
on Whatman 31 ET chr 2 cm2 paper. The papers
were rinsed with cold ethanol 66% (4 °C) for 30 min,
then twice with ethanol 66% at room temperature for
30 min. After removing the ethanol, the papers were
dipped in acetone for 2–3 min and dried. The papers
were then transferred into scintillation vials. The
radioactivity was measured using a liquid scintillation
counter (LKB Wallac 1219; Perkin Elmer, Woodbridge,
ON, Canada).
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Glucose uptake bioassay
C2C12 myocytes were grown in 12-well plates to 60%
confluence then differentiated into myotubes over a 7-
day period. On day 6 of differentiation, C2C12 cells were
treated overnight (16–18 h) with either 0.1% DMSO (ve-
hicle control), the maximal non-toxic concentrations of
CJ, FJ, each of the seven fractions (12.5 μg/mL) or each
the four pure compounds (Additional file 1: Table S1).
Metformin (400 μM) was used as a positive control in
similar conditions. After treatment, cells were rinsed
twice with a warm Krebs phosphate buffer (KPB:
20 mM Hepes, 4.05 mM Na2HPO4, 0.95 mM
NaH2PO4, 136 mM NaCl, 5 mM glucose, 4.7 mM
KCl, 1 mM CaCl2, 1 mM MgSO4, pH 7.4) then incu-
bated with KPB for 30 min at 37 °C. At this point,
insulin (100 nM) was added to specific wells to act as
another positive control (incubation in KPB buffer for
30 min). Cells were then rinsed twice with warm
glucose-free KPB, then incubated in glucose-free KPB
containing 0.5 μCi/mL 2-deoxy-D-3H-glucose (TRK-
383, Amersham Biosciences, Baie d’Urfé, Canada) for
10 min at 37 °C. After incubation, cells were kept on
ice and rinsed 3 times with ice-cold glucose-free KPB
then lysed in 0.5 μL of NaOH (0.1 M) for 30 min.
The lysates were transferred with 1 mL of water to
scintillation vials, then 4 mL of liquid scintillation
cocktail (Beckman Coulter, Fullerton, USA) was added
to each vial and incorporated radioactivity was mea-
sured using a liquid scintillation counter (LKB Wallac
1219; Perkin Elmer, Woodbridge, ON, Canada).
Statistical analysis
All data were reported as the mean ± SEM of 3 different
experiments with triplicates for each sample. Results
were analyzed by one-way analysis of variance (ANOVA)
(post-hoc pairwise comparisons were carried out with
Bonferroni correction). In case the requirement of
homogeneity of variances was not fulfilled, Games-
Howell test for post-hoc was used. All statistical analyses
were carried out using SPSS software, version 24 (IBM




After overnight treatment of H4IIE, HepG2 and differ-
entiated C2C12 cells with CJ, FJ, each of the seven frac-
tions or each of the four pure compounds at different
concentrations, LDH released and total LDH were mea-
sured for each condition. Additional file 1: Table S1
shows the maximum non-toxic concentration deter-
mined for each sample and each cell line based on the
results of LDH test.
Fermented blueberry juice and its fractions decrease
G6Pase activity and increase GS activation
As illustrated in Fig. 2a, FJ significantly decreased
G6Pase activity (31% reduction; p < 0.05) as compared
to vehicle control (0.1% DMSO). This effect repre-
sented roughly half of the effect of the insulin posi-
tive control (67% decrease). In contrast, CJ did not
induce a significant change in the activity of G6Pase.
After fractionation of FJ, the seven fractions were
tested in the G6Pase bioassay and all of them showed
varied, yet statistically significant, inhibitory effect on
the enzyme’s activity that ranged from 20 to 61%
when compared to the DMSO (0% inhibition refer-
ence; Fig. 2a).
Figure 2b presents results concerning GS activity. FJ
induced a significant increase in the enzyme’s activity
(2.3 fold increase, p < 0.001) identical to that of the
Fig. 2 Effect of FJ and its seven fractions on G6Pase (a) and GS (b)
activities. Results shown represent the change in G6Pase (a) and GS
(b) activity observed after overnight treatment of H4IIE and HepG2
cells with maximum non-toxic concentration of control (CJ) and
fermented (FJ) blueberry juice (both at 5 μg/mL) and the seven
fractions yielded from FJ (at 5 μg/mL). Results are expressed relative
to DMSO (0.1%) vehicle control (a: 0% inhibition; b: 100 % activity).
Insulin (100 nM) was used as a positive control. **: p<0.01 and ***:
p<0.001 significantly different from DMSO (n=3 in triplicates)
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positive control, insulin (2.3 fold activation). As observed
with G6Pase activity, CJ was without any significant ef-
fect. In addition, all seven fractions derived from FJ were
able to significantly increase the activity of GS and
ranged from 1.9- to 2.7-fold when compared to the
DMSO vehicle control (100% activation; Fig. 2b).
Phenolic fractions enhance glucose uptake in C2C12
muscle cells
When tested for their ability to enhance glucose up-
take in C2C12 muscle cells, FJ showed a 20% stimula-
tion of this uptake (p < 0.01) whereas CJ was without
any effect (similar to vehicle control, DMSO 0.1%;
Fig. 3). Insulin used as the positive control stimulated
glucose transport into cells by 33% (p < 0.001). The
phenolic fraction (F2) along with its subfractions F2.1
and F2.2, F2.3.2 were able to enhance glucose uptake
into muscle cells by 25, 18 and 15% respectively (p <
0.01). Bonferroni post hoc test did not reveal signifi-
cant differences between FJ, F2, F2.1, and F2.2. The
other fractions were without effect when compared to
vehicle control (100% activation; Fig. 3).
Identification and isolation of phenolic compounds from
the active fractions
Results of G6Pase and GS activity as well as glucose up-
take bioassays were used to guide the identification of
compounds found in the active fractions. HPLC analysis
confirmed that the three fractions F2, F2.1 and F2.2 were
composed mainly of four phenolic compounds: chloro-
genic acid (CA), gallic acid (GA), protocatechuic acid
(PA) and catechol (Cat). Compound identification was
confirmed by comparing retention times and UV-vis
profiles of each peak with respective standards (Fig. 4
and Additional file 1: Table S2). Calculation of phenolic
compounds concentrations was based on the external
standard method. The concentrations of individual
phenolic compounds in FJ were as follows: CA (3.0 mg/
g DW), GA (3.2 mg/g DW), PA (0.3 mg/g DW) and GA
(3.2 mg/g DW).
Identification of GA and Cat as the most active
compounds acting on key enzymes implicated in hepatic
glucose output
As mentioned above, the most active fractions (F2, F2.1
and F2.2) were rich in phenolic compounds mainly CA,
GA, PA and Cat. These compounds were tested at their
maximal non-toxic concentration in the G6Pase and the
GS assays. Two of the four compounds, namely CA and
PA, did not significantly decrease G6Pase activity as
compared to DMSO. In contrast, GA was able to reduce
the enzyme activity by 25% (p < 0.05) whereas Cat
yielded a 54% decrease in G6Pase activity (similar to the
positive control, insulin) compared to the vehicle control
DMSO 0.1% (p < 0.001, Fig. 5a). Games-Howell test
showed that difference between Cat and GA was statisti-
cally significant (p < 0.05). In the GS assay, all of the four
compounds were able to significantly increase the activ-
ity of the enzyme by about 2 fold (CA) or slightly less
(GA, PA and Cat) when compared to DMSO 0.1% ve-
hicle control (p < 0.05, Fig. 5b). These effects compared
favorably with the effect of insulin (2.3 fold increase). No
statistically significant differences were detected between
the compounds.
Enhancement of glucose uptake by CA, GA and Cat
Along with their ability to regulate key enzymes impli-
cated in hepatic glucose output, CA, GA and Cat signifi-
cantly enhanced glucose uptake in C2C12 cells by 15%
(p < 0,01), 16% (p < 0.05) and 43% (p < 0.001) respect-
ively. In contrast, PA had no effect when compared to
the vehicle control DMSO 0.1% (Fig. 6). Games-Howell
test revealed that Cat yielded the greatest activity, it dif-
fered significantly from CA (p < 0.01) and GA (p < 0.05).
CA and GA were not statistically different.
Discussion
Insulin resistance is an important risk factor for the de-
velopment of T2D. Along with the decrease in the phos-
phorylation of insulin receptor substrates (IRS-1 and
IRS-2) and in PI3-K activity observed in insulin resist-
ance, the translocation of glucose transporters and the
activity of key enzymes implicated in glucose homeosta-
sis are also reduced [24]. Despite the presence of many
hypoglycemic drugs in the market, the control of gly-
caemia is sometimes hard to achieve. Moreover, popula-
tions in Canada and the USA use natural health
Fig. 3 Effect of FJ and its seven fractions on 3H-deoxyglucose
uptake. Results shown represent 3H-deoxyglucoseuptake by C2C12
cells after overnight treatment with maximum non-toxic concentra-
tion of control (CJ) and fermented (FJ) blueberry juice (both at 12.5
μg/mL) and the seven fractions yielded from FJ (at 12.5 μg/mL).
Results are expressed as percentage relative to DMSO (0.1%) vehicle
control. Insulin (100 nM) was used as a positive control. **: p<0.01
and ***: p<0.001 significantly different from DMSO (n=3
in triplicates)
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products alone or in combination with their oral
hypoglycemic in order to better manage diabetes [3, 4].
Several parts of the Canadian “lowbush blueberry”
(Vaccinium Angustifolium Ait) plant were previously
shown by our group to exert antidiabetic activities [10].
A recent study by Klimis-Zakas et al. has reported the
ability of a wild blueberry-enriched diet to reduce meta-
bolic syndrome risk factors such as chronic inflamma-
tion and endothelial dysfunction in obese Zucker rats, a
rat model for metabolic dysfunction [25]. Meanwhile,
Matar and colleagues demonstrated that biotransform-
ation of blueberry juice by the Serratia vaccinii bacteria
conferred a new phytochemical profile to the juice [12].
HPLC evaluation of the phenolic profiles of the normal
and fermented juices detected differences in the con-
tents of flavonoids and organic acids. Notably, gallic
acid, which was not detected in normal juice, reached
concentrations that varied from 26.7 ± 0.9 to 64.6 ±
0.5 mg/kg FW in FJ. On the other hand, chlorogenic
acid was rather abundant in FJ, being present at a con-
centration of 852.7 ± 2.8 mg/kg FW. In general, total
phenolic content nearly tripled after 3 days of fermenta-
tion (from 1251.3 ± 278.7 to 3640.3 ± 201.1 mg of gallic
acid equivalent (GAE)/kg) and continued to increase
modestly thereafter to reach 3926.3 ± 194.3 mg of GAE/
kg after 7 days of fermentation [12]. Moreover, fermen-
ted blueberry juice (FJ) not only exhibited an increase in
phenolic content but was also characterized by more
pronounced antioxidant activities compared to the nor-
mal juice (CJ) [12, 13, 21]. Our laboratories therefore
combined efforts to examine the impact of fermentation
on the antidiabetic potential of wild blueberry
Fig. 4 HPLC profile for the different fractions derived from Fermented Blueberry Juice (FJ)
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preparations. We found that fermentation conferred to
blueberry juice the capacity to enhance glucose uptake
in muscle cells and adipocytes via phosphorylation of
AMPK [13].
In the current studies, we first chose to further evalu-
ate the antidiabetic potential of FJ by assessing rate-
limiting enzymes of gluconeogenesis (G6Pase) and
glycogen synthesis implicated in hepatic glucose output.
Indeed, the regulation of hepatic glucose production,
along with glucose utilization by peripheral tissues like
muscle and fat, are key regulators of systemic glycaemia
[17, 26]. We first compared effects of crude preparations
of control and fermented blueberry juice. Consistent
with our previous studies showing that fermentation
conferred antidiabetic potential, we found that fermen-
ted blueberry juice significantly affected hepatocellular
glucose homeostasis while control blueberry juice was
without effect. Indeed, FJ significantly inhibited G6Pase
(to a level roughly half as potent as insulin) and en-
hanced GS activity (to a level similar to insulin) in cul-
tured murine and human hepatocytes, respectively.
These results thus indicate that fermentation of blue-
berry juice also confers it the potential to control hepatic
glucose output by reducing glucose production and in-
creasing glucose storage. We also confirmed our previ-
ous finding in C2C12 cells [13] by demonstrating that
our fermented blueberry preparation increased glucose
transport whereas normal juice extract did not. This
ascertained that the current lyophilized preparations be-
haved similarly to the actual juice that was used in these
previous experiments.
Secondly and importantly, the current studies sought
to isolate active fractions/compounds participating in
the antidiabetic activity of the FJ in the muscle and liver
cell bioassays of glucose homeostasis by using a phyto-
chemical fractionation approach that we carried out pre-
viously to examine the protective effects of CJ on
cardiomyocytes [27]. This approach yielded seven poly-
phenolic fractions of FJ, which were tested in the
G6Pase, GS and glucose uptake bioassays. FJ fractions
were able to significantly decrease G6Pase activity to
levels ranging from 20 to 61%. The heteropolymer-
enriched fraction, F2.3.2, gave the highest effect, which
was very close to that of the positive control insulin. Un-
fortunately, the complexity of this fraction precluded
further sub-fractionation. Next in apparent potency were
the F2 and F2.1 fractions, the latter being enriched in
Fig. 5 Effect of CA, GA, PA and Cat isolated from the active fractions
of FJ on the activity of G6Pase (a) and GS (b). Results shown
represent the change in G6Pase (a) and GS (b) activities observed
after overnight treatment of H4IIE and HepG2 cells with maximum
non-toxic concentration of isolated compounds: CA (70.5 μM), GA
(147 μM), PA (162.2 μM) and Cat (45.5 μM). Results are expressed
relative to DMSO (0.1%) vehicle control (a: 0% inhibition; b: 100 %
activity). Insulin (100 nM) was used as a positive control. **: p<0.01
and ***: p<0.001 significantly different from DMSO (n=3
in triplicates)
Fig. 6 Effect of CA, GA, PA and Cat isolated from the active fractions
of FJ on 3H-deoxyglucose uptake. Results shown represent 3H-
deoxyglucose uptake by C2C12 cells after overnight treatment with
maximum non-toxic concentration of isolated compounds: CA (70.5
μM), GA (147 μM), PA (162.2 μM) and Cat (45.5 μM). Results are
expressed as percentage relative to DMSO (0.1%) vehicle control. In-
sulin (100 nM) was used as a positive control. *: p<0.05 and ***:
p<0.001 significantly different from DMSO (n=3 in triplicates)
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GA, PA and Cat. In contrast, all FJ phenolic fractions in-
creased the activity of GS within a relatively narrow
range (1.9- to 2.7- fold increase), which was comparable
to the action of the insulin positive control.
In terms of glucose uptake in skeletal muscle cells, on
the other hand, significant glucose transport activity was
associated only with three phenolic-enriched fractions,
namely F2, F2.1 and F2.2. Since all fractions were active
to varying degrees in both G6Pase and GS assays but
only these three phenolic fractions showed a significant
effect on glucose uptake, we examined in greater detail
the constituents of the latter fractions. HPLC analysis re-
vealed that the phenolic fractions contained mainly four
compounds, namely chlorogenic acid (CA), gallic acid
(GA), protochatecuic acid (PA) and catechol (Cat).
These compounds are known for their antioxidant activ-
ity. Many studies also showed additional beneficial ef-
fects of CA, GA and PA. Indeed, CA has demonstrated
anti-inflammatory, anti-diabetic, neuro-protective and
cardio-protective properties [28–31]. GA exerts anti-
diabetic activities [32], improves hyperglycaemia and
glucose tolerance [33], while offering protection against
diabetes complications, notably through cardio-
protective properties [34, 35]. On the other hand, PA
possesses anti-inflammatory [36, 37] and anti-apoptotic
properties [38]. It also improves angiogenesis [39] and
protects against hepatotoxicity and nephrotoxicity [40].
In contrast, and to our knowledge, no recent studies
have addressed effects of catechol on glucose metabol-
ism. Thus, our study is the first to reveal the effect of
these phenolic compounds on hepatic glucose homeo-
stasis and glucose transport in muscle.
The four compounds were able to increase GS activity
to levels similar to those observed for FJ and its active
fractions. GA and Cat showed stronger effects than the
two others on the reduction of G6Pase activity. This ef-
fect was close to that observed for FJ and its active frac-
tions. In terms of glucose transport, PA was inactive; GA
and CA had similar effects, whereas Cat had the most
pronounced activity. Interestingly, Cat stands out in this
study as having the best activity profile in almost all bio-
assays, yielding equivalent if not stronger effects than FJ
and its phenolic active fractions themselves.
Conclusion
Altogether, the results of this study confirmed that fer-
mentation of blueberry juice confers it antidiabetic po-
tential in liver and skeletal muscle cells through the
regulation of key hepatic enzymes implicated in gluco-
neogenesis and glycogen synthesis and the enhancement
of skeletal muscle glucose uptake. Using a phytochemical
fractionation approach, we now demonstrate that this
activity resides principally in phenolic fractions and can
be attributed, at least in part, to CA, GA, PA and Cat.
This is congruent with studies showing antidiabetic
properties for CA and GA, whereas it uncovers novel
beneficial actions for PA. As mentioned, however, of all
pure compounds in our study, Cat stood out as the most
promising constituent, showing activity similar to or
higher than the parent FJ (and even the insulin control)
in all three bioassays. Future studies will be needed to
further examine effects of flavonoids, anthocyanins, het-
eropolymers and proanthocyanins present in FJ.
Our study thus provides important insights into novel
potential antidiabetic molecules that are produced when
blueberry juice is fermented with Serratia vaccinii. Im-
portantly, the identified compounds represent quality
control tools that can be used to ensure the efficacy of
FJ and hence standardize FJ preparations.
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